INSULIN GLARGINE 300U/ML AND INSULIN GLARGINE 100U/ML SHOW EQUIPOTENT IN VIVO BLOOD GLUCOSE LOWERING WHEN ADMINISTERED INTRAVENOUSLY IN DOGS

被引：0
|
作者：
Werner, U. [1 ]
Korn, M. [1 ]
Tennagels, N. [1 ]
机构：
[1] Sanofi, Diabet Div, Frankfurt, Germany
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2016年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
296
引用
收藏
页码：A119 / A119
页数：1
相关论文
共 50 条
  • [31] Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life
    Oriot, Philippe
    Jeremie, Wawrzyniak
    Buysschaert, Martin
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2018, 13 (03) : 167 - 171
  • [32] An Exploratory Study to Evaluate the Glycemic Variability by Continuous Glucose Monitoring (CGM) with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Patients with Type 2 Diabetes
    Franco, Denise R.
    Visconti, Guilherme D.
    Feder, Cecilia
    Baptista, Juliana
    Vianna, Andre G.
    Guimaraes, Mariana T.
    Souza, Flavia V.
    Tagata, Luciana A.
    Eliaschewitz, Freddy
    [J]. DIABETES, 2020, 69
  • [33] Is hypoglycaemia a modifiable patient risk in type 2 diabetes: A pooled analysis of insulin glargine 300 U/mL (Gla-300) vs 100U/mL (Gla-100) trials?
    Zhang, Q.
    Rosenstock, J.
    Gerrits, C.
    Liao, L.
    Chew, P.
    [J]. DIABETOLOGIA, 2015, 58 : S472 - S472
  • [34] GLYCEMIC CONTROL AND HYPOGLYCEMIA WITH INSULIN GLARGINE 300U/ML VS GLARGINE 100U/ML IN T2DM IN A PATIENT-LEVEL META-ANALYSIS OF 1-YEAR PHASE 3A EDITION STUDIES
    Ritzel, R.
    Roussel, R.
    Giaccari, A.
    Vora, J.
    Grisoni, M. L.
    Brulle-Wohlhueter, C.
    Glezer, S.
    Yki-Jarvinen, H.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A118 - A118
  • [35] Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation
    Owens, D. R.
    Bailey, T. S.
    Fanelli, C. G.
    Yale, J. -F.
    Bolli, G. B.
    [J]. DIABETES & METABOLISM, 2019, 45 (04) : 330 - 340
  • [36] Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naive people with type 2 diabetes: The EDITION AP randomized controlled trial
    Ji, Linong
    Kang, Eun Seok
    Dong, XiaoLin
    Li, Ling
    Yuan, GuoYue
    Shang, Shuhua
    Niemoeller, Elisabeth
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (04): : 612 - 621
  • [37] Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats
    Gilor, C.
    Culp, W.
    Ghandi, S.
    do Carmo Emidio e Silva, J. A.
    Ladhar, A.
    Hulsebosch, S.
    [J]. DOMESTIC ANIMAL ENDOCRINOLOGY, 2019, 69 : 19 - 29
  • [38] PREDICTION OF HYPOGLYCEMIA IN PATIENTS TREATED WITH INSULIN GLARGINE 300 U/ML FOR BASAL INSULIN THERAPY
    Takeishi, S.
    Inoue, T.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A176 - A177
  • [39] Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important?
    Bonadonna, Riccardo C.
    Renard, Eric
    Cheng, Alice
    Fritsche, Andreas
    Cali, Anna
    Melas-Melt, Lydie
    Umpierrez, Guillermo E.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 142 : 19 - 25
  • [40] REDUCED HYPOGLYCEMIA AND COMPARABLE EFFICACY WITH INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES ACHIEVING DIFFERENT LEVELS OF PREBREAKFAST SELF-MONITORED PLASMA GLUCOSE
    Bailey, Timothy S.
    Odugbesan, Ola
    Gill, J. K.
    Nikonova, Elena, V
    Chao, Jason
    Reid, Timothy
    [J]. ENDOCRINE PRACTICE, 2018, 24 (11) : 973 - 981
12345